Compare Infosys Limited (INFY) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Infosys Limited trades at $10.84 (market cap $41.74B), while Iovance Biotherapeutics Inc. Common Stock trades at $13.43 (market cap $6.04B). The key difference: Infosys Limited is far larger — about 6.9× Iovance Biotherapeutics Inc. Common Stock's market cap, and Infosys Limited pays a 4.89% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| INFY | IOVA | |
|---|---|---|
Market Cap | $41.74B | $6.04B |
Volume | 31,354,285 | 14,805,993 |
Sector | Technology | Health |
52-Week High | $20.22 | $14.82 |
52-Week Low | $10.49 | $1.81 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $39.48B | $5.97B |
Dividend Yield | 4.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Infosys (INFY) trades at $10.55, showing no change in the latest session. The stock is in a bearish technical trend with key support at $10 and resistance at $11. Fundamentally, the company reported strong profitability with a net income margin of 16.37% and ROE of 32.12% for 2025. Recent news highlights strategic AI collaborations, including with Columbia University and ABN Amro, to drive innovation. However, cash flow trends show a projected decline in net cash flow for 2026.
The outlook for INFY is mixed. Positive fundamentals and strategic partnerships offer growth potential, but bearish technicals and a projected cash flow decline pose risks. Analyst consensus is a 'Hold' with a price target of $11.48, suggesting limited near-term upside. Investors should weigh strong profitability against execution risks in a competitive IT services market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
